Last reviewed · How we verify
Betaferon/Betaseron
Betaferon is interferon beta-1b, which activates immune cells and reduces inflammatory responses in the central nervous system to slow disease progression.
Betaferon is interferon beta-1b, which activates immune cells and reduces inflammatory responses in the central nervous system to slow disease progression. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis with active disease.
At a glance
| Generic name | Betaferon/Betaseron |
|---|---|
| Sponsor | Bayer |
| Drug class | Interferon beta |
| Target | Interferon beta receptor (IFNBR) |
| Modality | Small molecule |
| Therapeutic area | Immunology/Neurology |
| Phase | FDA-approved |
Mechanism of action
Interferon beta-1b is a recombinant cytokine that enhances natural killer cell activity and increases expression of major histocompatibility complex (MHC) molecules on immune cells. This modulates the immune response in multiple sclerosis by reducing pro-inflammatory cytokine production and decreasing the migration of immune cells across the blood-brain barrier, thereby reducing demyelination and neuroinflammation.
Approved indications
- Relapsing-remitting multiple sclerosis
- Secondary progressive multiple sclerosis with active disease
Common side effects
- Injection site reactions
- Flu-like symptoms (fever, chills, myalgia)
- Headache
- Fatigue
- Depression
- Elevated liver enzymes
- Leukopenia
Key clinical trials
- An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (PHASE4)
- US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
- Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
- Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (PHASE2)
- Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (PHASE2, PHASE3)
- Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betaferon/Betaseron CI brief — competitive landscape report
- Betaferon/Betaseron updates RSS · CI watch RSS
- Bayer portfolio CI